Guidelines Update: Differentiated Thyroid Cancer
Credit Available - See Credits tab below.
Total Credits: 1.25 including 1 AMA PRA Category 1 Credit™
- Bundle(s):
- ATA 2025 Bundle
- Duration:
- 1 Hour 16 Minutes
- Format:
- Audio and Video
Description
Accreditation
The American Thyroid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American Thyroid Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American Thyroid Association ensures that anyone in a position to control the content of the educational activity (planners/speakers/authors/discussants/moderators) disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”) held in the last 24 months. The faculty have nothing to disclose.
The ACCME also requires that ATA manage any reported relevant financial relationships and eliminate the potential for bias during the educational activity. Any relevant financial relationships noted have been mitigated. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
R. Michael Tuttle - (Research Funding)
Julie Ann Sosa - Exelisis; Eli Lilly; Lilly (Research Funding); Novo Nordisk; Astra Zeneca; Eli Lilly (Consultant)
Matt Ringel - Nothing to disclose
Credits
Faculty
Julie Ann Sosa, MD - Guideline Co-Chair Related Seminars and Products
Julie Ann Sosa, MD, MA, FACS is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Dr Sosa came to UCSF in 2018 from Duke. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH-funded investigator and author of more than 300 peer-reviewed publications, 2 books, and 57 book chapters, largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery and is an editor of Greenfield’s Surgery: Scientific Principles and Practice. She has mentored more than 90 students, residents, and fellows, for which she was recognized with the Lewis E. Braverman Distinguished Lectureship Award from the ATA. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.
Matt Ringel, MD - Guideline Co-Chair Related Seminars and Products
Matthew Ringel, MD is a professor and director of the Division of Endocrinology, Metabolism and Diabetes at The Ohio State University, where he also serves as co-leader of the Cancer Biology Program at the OSUCCC – James and holds the Ralph W. Kurtz Chair in Hormonology. Dr. Ringel focuses his research on molecular mechanisms involved in thyroid cancer invasion and metastasis, with an active interest in new drug testing for thyroid cancer therapy. Among his current research activities is serving as principal investigator (PI) for a National Cancer Institute (NCI) grant-funded study of the “Role of P21-Activated Kinases in Thyroid Cancer.” Dr. Ringel and colleagues have identified a potentially important pathway (p21 activated kinase, or PAK) downstream of the BRAF gene that may be involved in the progression of papillary thyroid cancer, which is incurable when metastatic and progressive. His team hopes to determine the relevance of the PAK pathway in vivo, clarify the mechanism by which it is activated and test novel compounds that block PAK activation with a goal of determining whether PAK is a viable therapeutic target. Dr. Ringel has also served as PI for a multimillion-dollar, NCI-funded program project grant (PPG) to study “Genetic and Signaling Pathways in Epithelial Thyroid Cancer” and for an NCI-funded Specialized Program of Research Excellence (SPORE) grant to help improve the lives of patients with thyroid cancer. Both grants entailed several interactive projects and multiple investigators at Ohio State and other academic institutions.
Alternate Options
|
Decoding Thyroid Cancer: Unraveling the Impact of Epigenetics on Development, Tumor Microenvironment, and Immune Response
Original Program Date: 10/31/2024 |